497 reports of this reaction
1.9% of all ERLOTINIB HYDROCHLORIDE reports
#11 most reported adverse reaction
ANAEMIA is the #11 most commonly reported adverse reaction for ERLOTINIB HYDROCHLORIDE, manufactured by Armas Pharmaceuticals Inc.. There are 497 FDA adverse event reports linking ERLOTINIB HYDROCHLORIDE to ANAEMIA. This represents approximately 1.9% of all 25,894 adverse event reports for this drug.
Patients taking ERLOTINIB HYDROCHLORIDE who experience anaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANAEMIA is a less commonly reported adverse event for ERLOTINIB HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to anaemia, the following adverse reactions have been reported for ERLOTINIB HYDROCHLORIDE:
The following drugs have also been linked to anaemia in FDA adverse event reports:
ANAEMIA has been reported as an adverse event in 497 FDA reports for ERLOTINIB HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANAEMIA accounts for approximately 1.9% of all adverse event reports for ERLOTINIB HYDROCHLORIDE, making it a notable side effect.
If you experience anaemia while taking ERLOTINIB HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.